Glenmark Life Sciences has reported results for first quarter ended June 30, 2024 (Q1FY25).
The company has reported 17.70% fall in net profit at Rs 111.48 crore for Q1FY25 as compared to Rs 135.45 crore for the same quarter in the previous year. However, total income of the company increased by 2.38% at Rs 594.11 crore for Q1FY25 as compared to Rs 580.30 crore for the corresponding quarter previous year.
Glenmark Life Sciences is in the business of making high-quality drugs by unlocking the possibilities of science.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1625.00 |
| Dr. Reddys Lab | 1317.05 |
| Cipla | 1287.20 |
| Zydus Lifesciences | 929.65 |
| Lupin | 2297.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: